Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
Joseph A SparanoMichael CragerRobert J GrayGong TangJess HoagFrederick L BaehnerSteven ShakDella F MakowerKathy S AlbainDaniel F HayesCharles E GeyerElizabeth C DeesMatthew P GoetzJohn A OlsonTracy LivelySunil S BadveThomas J SaphnerTimothy J WhelanVirginia G KaklamaniNorman WolmarkGeorge W SledgeSalomon M StemmerPublished in: NEJM evidence (2024)
The 21-gene RS is prognostic for distant recurrence and overall survival in early breast cancer. A model integrating the 21-gene RS and clinicopathologic factors improved estimates of distant recurrence risk compared with either used individually and stratified late distant recurrence risk. (Funded by the National Cancer Institute, National Institutes of Health [U10CA180820, U10CA180794, UG1CA189859, U10CA180868, and U10CA180822] and others.).